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Abstract
BORIS, or CTCFL, the so called Brother of the Regulator of Imprinted Sites because of the extensive homology in
the central DNA binding region of the protein to the related regulator, CTCF, is expressed in early gametogenesis
and in multiple cancers but not in differentiated somatic cells. Thus it is a member of the cancer testes antigen
group (CTAs). Since BORIS and CTCF target common DNA binding sites, these proteins function on two levels, the
first level is their regulation via the methylation context of the DNA target site and the second level is their distinct
and different epigenetic associations due to differences in the non-homologous termini of the proteins. The
regulation on both of these levels is extensive and complex and the sphere of influence of each of these proteins
is associated with vastly different cellular signaling processes. On the level of gene expression, BORIS has three
known promoters and multiple spliced mRNAs which adds another level of complexity to this intriguing regulator.
BORIS expression is observed in the majority of cancer tissues and cell lines analyzed up to today. The expression
profile and essential role of BORIS in cancer make this molecule very attractive target for cancer immunotherapy.
This review summarizes what is known about BORIS regarding its expression, structure, and function and then
presents some theoretical considerations with respect to its genome wide influence and its potential for use as a
vaccine for cancer immunotherapy.
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Introduction
BORIS is a complex and highly versatile transcription
factor sporadically expressed in numerous mammalian
cells and member of the cancer-testis antigen (CTA)
family, a group of genes expressed in the testis and
abnormally expressed in cancer malignancies [1]. Var-
ious studies have attempted to elucidate the role of
BORIS in different cell types, however the exact
mechanisms by which it interacts with the genome and
the extent to which it influences cellular processes
remain largely a mystery. BORIS appeared fairly early in
the evolutionary tree most likely through a full-length
genomic duplication of CTCF before the mammalian-
reptilian split [2] which occurred about 310 million
years ago [3,4]. BORIS is the only known paralog of
CTCF a protein that has been called the “master weaver
of the genome”[5], and for which a staggering 14,000–
25,000 potential binding sites have been identified in the
human genome [5-7]. Both of the proteins have a cen-
tral 11 zinc finger the DNA binding region with very
similar amino acid sequence which has conserved more
than a 74% residue identity in humans [2,8]. This indi-
cates a tightly controlled evolutionary selection process
to conserve a highly specific genome-wide DNA binding
ability which suggests a very important and likely critical
role for BORIS in chromatin functions. Indeed, BORIS
has been implicated in numerous regulatory functions
including cell proliferation [9], activation of other CTA
genes [10,11], spermatogenesis [12], and human preim-
plantation development [13], however the extent and
the importance of it’s cellular role is still not well under-
stood. The difficulty in defining this role is due in part
to the fact that BORIS expression is inconsistent in
many cells, particularly cancer (Table 1). An evaluation
of the functional characteristics of the BORIS promoter
region has shown that BORIS expression can be
repressed by at least three things: DNA methylation, the
* Correspondence: ecarrier@ucsd.edu
2Department of Medicine, University of California, San Diego, CA 92093, USA
Full list of author information is available at the end of the article
de Necochea-Campion et al. Journal of Translational Medicine 2011, 9:213
http://www.translational-medicine.com/content/9/1/213
© 2011 de Necochea-Campion et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
presence of CTCF or the presence of p53 [14]. Further-
more, the BORIS promoter region actually contains
three differentially regulated promoters which control
expression of the BORIS gene and produce 5 alterna-
tively spliced mRNAs [14]. Initially, those authors
hypothesized that the function of the 5’ mRNA variants
was related to transcript stability since they all seemed
to generate the same protein product despite differences
in their 5’ non-coding regions. More recently the same
research group identified a much larger number of alter-
natively spliced BORIS mRNA variants detecting a total
of 23 different BORIS isoforms expressed in human
cells [8]. Some of these isoforms encode specific amino
and carboxyl translational frame shifts or produce pro-
teins with distinct zinc-finger combinations. Undoubt-
edly, all of these characteristics can affect the specific
chromatin regulatory functions of BORIS. This seems to
be supported by the finding that distinct isoform expres-
sion patterns are detected in different cell types [8].
DNA Binding Ability
Most of what is known about the specific way that
BORIS utilizes combinations of zinc fingers (ZFs) to
bind to DNA has been inferred from studies done with
CTCF which found that specific combinations of zinc-
fingers are used to bind to highly diverse target
sequences. This was determined through extensive
experimental analyses involving sequential deletion of
ZFs and subsequent characterization of mutant CTCF
nucleotide interactions [15]. Due to the high degree of
sequence similarity, we assume that BORIS uses the
same ZF combinations when binding the same specific
target sequences, however other factors may influence
this protein’s overall ability to bind to certain genomic
regions. The recently characterized isoforms of the
BORIS transcript were found to include one splicing
variant which codes for a protein containing an entirely
new zinc finger formed by splicing together two ZF
halves (ZF4 and ZF9)[8]. The 23 BORIS isoforms were
found to translate into 17 distinct polypeptide products
and the ability of these 17 proteins to bind to 2 specific
genomic regions was studied. These authors found that
9/17 isoforms could bind to a specific IGF2/H19
imprinting control region (ICR) target probe, while 13/
17 isoforms could bind to a testis-specific CST gene
promoter. This difference made it possible to determine
that 9 of the BORIS zinc-fingers were involved in bind-
ing to the H19 ICR site while only 5 were needed for
binding to the CST promoter.
DNA binding properties of BORIS compared to CTCF
Several genomic factors may be involved in determining
whether BORIS or CTCF binds to a specific region,
however numerous studies suggest that DNA methyla-
tion plays an important role in this process. Most stu-
dies find that CTCF does not bind to sequences of
DNA when they are methylated, such as regulatory
regions of hTERT [14] and rDNA [16], or insulator
regions surrounding MHC-II genes [17]. A few authors
have compared the binding properties of both BORIS
and CTCF. In one study that analyzed the SCA 7 locus,
it was reported that neither BORIS nor CTCF could
bind to methylated DNA sequences [18]. Another study
which analyzed histone methylation patterns in the
BAG-1 promoter region, found CTCF binding to be
associated with a nonpermissive chromatin status char-
acterized by low dimethyl-H3-K4/dimethyl-H3-K9 ratio
while BORIS binding appeared to coincide with changes
that resulted in a permissive chromatin status [19].
Intriguingly, these authors did not find any significant
differences in the level of DNA methylation in the
BAG-1 region associated with BORIS or CTCF binding.
There has been some controversy in the literature
regarding the extent of the influence of DNA
Table 1 Variability in the frequency of BORIS expression detected in cancer (NT = not tested)
Type of Cancer Cell Line Expression Primary Tumor Sample References
Breast 8%-100% 71%*-92%* [11]* [14][49]* [42]
Melanoma 90%-100% 27%* [11][14][43]*
Colon 75-100% 80%* [11]* [14]
Prostate 50%-60% 90%* [11]* [62]
Ovarian 40%-100% NT [14,39]
Lung 60%-100% NT [11][14]
Leukemia 100% NT [14]
Bladder 27% NT [62]
Uterine 77% NT [6]
Endometrial 77% NT [6]
Osteosarcomas NT 38%* [63]*
Squamous cell carcinomas NT 81%* [54]*
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methylation over BORIS and CTCF binding ability, how-
ever only a few target sites have really been analyzed in
detail. One of these is the IFG2/H19 ICR where it was
found that neither CTCF nor any of the 9 BORIS iso-
forms that could bind to this target site, could do so after
the H19 ICR probe was methylated in vitro by SssI
methyltransferase [8]. In contrast, others reported that
BORIS binding to this region was largely methylation
insensitive since a large number of BORIS-DNA interac-
tions were observed in methylated DNA segments from
this region [20]. This discrepancy may arise from the use
of different experimental and analytical techniques.
Whereas one group used EMSA assays with labeled
probes specific to the 6th CTCF target site in the H19-
IGF2 [8], the other group performed ChIP assays that
compared BORIS and CTCF binding to genomic DNA
fragments containing a 360bp segment from the region
of interest [20]. With ChIP assays it is difficult to deter-
mine the exact binding location within the area that is
being analyzed [21], so it is possible that the BORIS bind-
ing observed in this experiment was in a non-methylated
segment. However, these authors [20] then carried out in
vitro experiments where they did observe BORIS binding
to an SssI-methylated H19 CTCF binding site probe. So
it is possible that the influence of DNA methylation over
BORIS vs. CTCF binding is very site specific. This is par-
ticularly evident in another study where the authors ana-
lyzed DNA methylation patterns of 23CpG dinucleotides
over a 700bp segment of the MAGE-A1 regulatory region
and determined their influence on CTCF and BORIS
binding to this region [11]. Surprisingly, they found that
strong CTCF binding occurred in vivo when the area was
largely methylated, and that binding could also occur to a
methylated target probe from this region in vitro.
Furthermore, the switch from CTCF to BORIS occu-
pancy occurred when the area was demethylated either
by 5azadC treatment or conditional expression of BORIS
through transient transfection [11]. Thus the presence of
BORIS was associated not only with CTCF displacement
but also with further demethylation of the MAGE-A1
regulatory region and activation of gene expression [11].
In summary, many questions remain about the specific
mechanisms connected with BORIS and CTCF binding
abilities and to understand why the influence of DNA
methylation is so prevalent under some circumstances
and not others. Much investigation is still needed to
understand how DNA methylation of specific sequences
or regions relative to the specific CTCF/BORIS binding
site can influence binding ability as well as to understand
how this may vary among distinct BORIS isoforms.
Gene Regulation and Protein Partners
Some studies have shown that the effects of BORIS
binding to specific genomic regions are very different
from those of CTCF. In fact, these proteins generally
exert exact opposite effects over gene expression. Typi-
cally BORIS is found to activate gene expression and be
involved in cell proliferation, while CTCF represses gene
expression and inhibits cell proliferation [9,20]. Specifi-
cally, BORIS has been reported to activate and CTCF to
represses expression of MAGE-A [11], BORIS [14],
BAG-1 [19], NY-ESO-1 [22], and hTERT [23]. It is not
surprising that these proteins are associated with oppos-
ing functional outcomes, given the significant sequence
and structural differences of their amino and carboxyl
extremes. A comparison of BORIS and CTCF reveals
that in spite of the high degree of similarity (74.1% iden-
tity) conserved in the DNA binding region, the ends of
the proteins share less than 15% sequence identity [2].
Furthermore, both CTCF and BORIS are known to
associate with an extensive list of different protein inter-
acting partners (Figure 1) which essentially change the
structure of the DNA-bound protein complex, and pre-
sumably modify its specific activity and chromatin regu-
lating abilities. Therefore, it may actually be the protein
partners of CTCF and BORIS that ultimately determine
their specific cellular function at a specific location. The
importance of these interactions seems to be supported
by the fact that an analysis of the amino and carboxyl
protein domains of BORIS shows them to be largely
unstructured molecules suggesting that their architec-
ture may be organized through their protein associations
[24].
In Figure 1 we see many of the human interacting
protein partners of BORIS which were identified using
yeast 2-hybrid isolation techniques [25]. Several BORIS
N-terminus segments of varying length were used as
bait and most of the isolated proteins were able to bind
many of these bait targets. This makes it likely that sev-
eral of the BORIS protein partners interact with more
than one of its 17 paraprotein alternative splicing var-
iants. It was reported that almost all of these BORIS
splicing variants conserve a 258 base pair N-terminus
region [26], which may demonstrate the importance of
conserving the protein interactions that occur within
this protein domain. It is interesting to note that when
the specific interacting partners of the N-terminus of
BORIS are compared with interacting partners of CTCF,
only CHD8 is identified as an interacting partner of
both (Figure 1). Considering that CHD8 is found to
interact with both the unique N-terminus sequence of
BORIS [25], and the central zinc finger region of CTCF
[27], it is intriguing to speculate on the distinct genomic
role that may result from these distinct interactions. It
is thought that the role of the CTCF-CHD8 interaction
regulates the insulator function of CTCF [28], but the
effects of it’s interaction with BORIS have not been stu-
died. It is possible that some of the interacting partners
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known to associate directly with the zinc finger DNA
binding domain of CTCF, such as Sin3A [29,30], YB-1
[31], and Oct4 [32] may also interact with the same
region of the BORIS protein due to it’s sequence simi-
larity. In fact, a common zinc finger region interacting
partner, UBF, was recently identified [16] (Figure 1).
UBF forms part of the RNA polymerase I Complex
which transcribes ribosomal RNA [16]. It is believed
that the CTCF-UBF interaction may help prepare ribo-
somal DNA for transcription [16], but the effects of the
BORIS-UBF interaction are yet to be studied.
Epigenetic Regulatory Mechanisms
Although the importance of the BORIS interacting pro-
tein partners has been recognized, very few studies have
actually attempted to elucidate the specific function of
these protein associations. One study found that BORIS
acted as a scaffold onto which the BAT3 and then
SET1A proteins were recruited to the myc and BRCA1
promoters [19]. It was shown that this protein complex
increased H3K4 methylation and promoted gene
expression at these two pro-carcinogenic promoters. A
second study analyzed BORIS interactions in the mouse
genome and found that it recruited the PRMT7 protein
to the H19 ICR site in the developing testis [33].
PRMT7 is a protein arginine methyltransferase known
to catalyze specific chromatin histone methylations
[33,34]. It was shown that the BORIS could bind to
both the H2 and H4 histones at the H19 ICR site and
the BORIS-PRMT7 interaction directly correlated to an
enrichment in symmetrical dimethylation of arginine 3
at histone 4(H4R3me2)[33]. A third study found both
BORIS and Sp-1 proteins present at NY-ESO-1 promo-
ters in lung cancer cells [10]. After demonstrating that
these proteins directly interacted, these authors con-
cluded that BORIS recruits Sp-1 and forms a transcrip-
tional regulatory complex that activates NY-ESO-1
expression in these cancer cells. In each of these studies
it was concluded that the presence of BORIS was essen-
tial for proper positioning of the other proteins. This
leaves us to question if the primary regulatory role of
BORIS could be to function as a type of chromatin
Figure 1 Known human interacting protein partners of BORIS (yellow) and CTCF (blue). Squares indicate the proteins observed to
interact with both BORIS and CTCF. van de Nobelen et al., 2010 identified UBF as a common interacting partner for both BORIS and CTCF
[16]. All other proteins shown to associate with BORIS were identified by Nguyen et al., 2008 and isolated using yeast 2-hybrid screening
techniques with N-terminus segments of the BORIS protein as bait [25]. Proteins shown to interact with CTCF were all discussed in an excellent
review published by Ohlsson et al., 2010 [27].
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beacon which attracts and orients other proteins prop-
erly in the genome.
A primary role for BORIS as a genomic recruiter
seems likely given the number of nuclear proteins
known to interact with it’s unique N-terminus sequence
(Figure 1), the fact that a 258 residue N-terminus seg-
ment highly conserved among all of its recently discov-
ered isoforms [8], and the difficulty in understanding
and defining the specific cellular role of BORIS despite
its discovery about 10 years ago [26]. We propose that
in addition to some of the specific regulatory functions
that have been reported for BORIS, it also modulates
epigenetic changes on a massive scale. This is due to
the fact that many of the protein partners that interact
with BORIS are also known to interact with histone
methylating complexes (Figure 2). It is possible to envi-
sion a scenario in which specific isoforms of BORIS
bind to DNA, and then attract specific interacting part-
ners, which in turn attract and ultimately organize
methytransferase complexes correctly in the genome.
This could result in epigenetic remodeling on a massive
or even a very specific scale depending on the abun-
dance or role of a particular BORIS isoform as well as
the affinity for a specific interacting partner, and the
likelihood that this partner then associates with methyl-
transferases as depicted in Figure 2. It is known that the
specific methyltransferase complex known to associate
with the potential interacting partners of BORIS [35]
does catalyze H3K4 dimethylations associated with
active gene transcription [36-38]. And the presence of
BORIS in specific genomic locations is generally linked
to active gene expression. In addition, some studies have
analyzed the correlation between BORIS expression and
H3K4 chromatin methylation status demonstrating a
connection to specific epigenetic changes. It was found
that cellular conditions that increase expression of
BORIS are linked to increased levels of H3K4me2 in the
BORIS promoter region [39], known to contain several
BORIS binding sites [14]. Suppression of BORIS expres-
sion has an opposite effect. Knockdown of BORIS
expression in human colon carcinoma cell lines
decreases H3K4 methylation as well as expression of
myc, BRCA1 and H19 [25] Another study found that
suppression of BORIS expression decreases H3K4
methylation at the BAG-1 promoter resulting in
decreased expression of this gene [19]. In all, the results
of these studies suggest that BORIS may play a central
role in genome wide histone methylation modifications.
Role in the Testis
Part of the difficulty in understanding the cellular role
of BORIS has been the increasing number of diverse cell
types in which BORIS expression has been documented.
Traditionally, “normal” expression of BORIS was
Figure 2 Shown are the proteins known to bind to the N-terminus region of the BORIS which have the potential to interact with
methyltransferases with catalyze H3K4 methylations. Solid lines represent documented protein complexes [25], and dashed lines represent
the potential for additionally formed protein complexes since it is unknown if these interactions [35] also take place in the presence of BORIS.
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described as being confined to the testis and involving a
role in spermatogenesis [9,14]. It was thought that since
this is the only place where CTCF is not expressed [9],
DNA-binding competition could be avoided between
these proteins, and thus all BORIS activity could be
linked to normal functions. Still, the role of BORIS in
spermatogenesis has not been well defined. It has been
speculated that the role of BORIS in male germline cells
involves the epigenetic regulation responsible for DNA
methylation of imprinting control regions [33]. Also it
has been seen to bind to and activate the promoter of a
cancer-testis gene, SPAN-X [6]. Recently it was shown
that BORIS knockout mice have smaller testes and
defective sperm production, although surprisingly they
are still fertile [12]. The absence of BORIS causes a dra-
matic reduction in the expression of the CST gene,
which has a critical role in meiosis and causes a signifi-
cant delay in sperm production [12]. In all, these studies
indicate that in testis tissues BORIS regulates gene
expression and may play an important role in meiosis
necessary to produce the haploid sperm.
Role in Cancer
Expression of BORIS in cancer has traditionally been
viewed as an aberrant phenomenon although there has
been some controversy regarding the importance of its
role in these cells. In epithelial ovarian cancer the
BORIS/CTCF expression ratio is also associated with
increased stage and decreased overall and progression-
free survival [40]. It has been suggested that the expres-
sion of BORIS displaces CTCF in the genome and leads
to proliferation of cancer cells [26]. The results of some
studies seem to support this theory because BORIS has
been seen to bind to the promoters and activate expres-
sion of several CTA oncogenes [11,22]. Intriguingly, one
study reported that silencing BORIS expression in a
breast cancer cell line has a concentration dependent
apoptotic effect on these cells [41]. In contrast, another
publication reports that BORIS is not expressed in the
majority of breast cancer cell lines or tumors and is
unlikely to play a role in tumorigenesis [42]. These
authors propose that the use of sensitive quantitative
techniques to measure BORIS expression may be a rea-
son for their contradictory findings. However, others
have found that even when BORIS expression is forced
in cancer cells it does not automatically lead to the acti-
vation of the cancer-testis genes it is proposed to regu-
late [43,44]. One possibility is that the presence of
BORIS alone is insufficient to displace CTCF binding
and repression over CTA gene expression in the gen-
ome. Another possibility is that a particular isoform of
BORIS is necessary for the regulation of these CTA
genes. In fact, it is only when a general expression of
BORIS is induced in cancer cells by the addition of the
DNA-demethylating agent 5-azadC [10,11,22], as
opposed to using genetic constructs [43,44] that it is
associated with the activation of CTA genes. These con-
flicting findings are difficult to interpret due to a lack of
knowledge about the roles of different BORIS isoforms,
their potential interacting partners, and the genes they
regulate or influence. Interestingly, the entire genomic
region of the BORIS locus was studied recently and two
minisatellite loci (BORIS-MS1 and BORIS-MS2)
upstream of BORIS have been identified [45]. In addi-
tion, analyses of allelic variations in the minisatellites of
BORIS were found to be significantly related to suscept-
ibility to breast cancer in young patients within the Kor-
ean population studied [45].
Although the detection of BORIS in cancers seem to
be well documented, other important questions also
remain to be answered, including how frequently BORIS
is expressed in different cancers and how much BORIS
is expressed per cell. Some authors argue that the
expression of mRNA below 1 copy per cell should be
ignored [43]. This statement may be true if all cancer
cells were to express BORIS. However, it is a common
knowledge that cancer cells within a tumor are very het-
erogeneous and only a fraction of cells may express
BORIS then the question would be what is this fraction
of BORIS expressing cells and how important is it for
cancer development. Other authors suggest that in
order to compete with CTCF at certain sites BORIS
should be expressed at levels comparable with CTCF
[42]. However, it is extremely unlikely that the amount
of BORIS be at the same level as CTCF as it will com-
pete out CTCF at majority of its binding sites creating a
situation similar to CTCF knock-out that is reported to
be lethal to cells. Theoretically, if only few CTCF sites
are occupied by BORIS that might be sufficient to
achieve growth advantage over the cells that maintain
CTCF binding on these sites. But that means that very
low expression by BORIS might be enough to compete
out CTCF from few sites provided nuclear compartmen-
talization selectively delivers BORIS protein to some
sites and not to the other. Moreover, there are two pub-
lications that reported selective loss of CTCF binding
from p16ink4a locus [46] and p53 promoter [47]. Clearly,
genome-wide ChIPs with good anti-BORIS antibodies
on tumor cell lines and primary tumors will answer
those important questions.
BORIS expression in other cell types
Analysis of BORIS expression in human cells and tissues
has revealed several other cell types that express this
protein. These include the ovary, leukocytes from breast
cancer patients, and embryonic stem cells. Similar to it’s
function in spermatogenesis, BORIS expression in the
ovary is thought to have a role in meiosis during
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oogenesis [13]. The expression of BORIS in oocytes and
it’s disappearance in cleavage stage embryos is found to
coincide closely with genome-wide events of DNA
demethylation (oocytes) and then re-methylation (clea-
vage stage embryos)[48]. BORIS expression can also
detected in leukocytes isolated from the blood of breast
cancer patients [49]. Here quantities of BORIS protein
correlate strongly with tumor size and thus it’s potential
for use as a cancer biomarker has been evaluated [49]. It
is possible that BORIS may play a role in the antitu-
moral response of these cells however its exact function
is unknown. Again, part of the difficulty in understand-
ing the role of BORIS in these diverse cell types can be
attributed to a lack of knowledge about the expression
patterns of specific isoforms and their extensive protein
interactions which probably define the specific cellular
function of BORIS at a certain moment or specific
genomic location.
BORIS expression is not detected in cleavage stage
embryos or human blastocysts, however it can be
detected in human embryonic stem (hES) cells isolated
from their inner cell mass [13]. Moreover, it was shown
that BORIS expression disappears upon hES cells differ-
entiation [8]. The function of BORIS in human embryo-
nic stem cells is not clear, however, it is thought to be
associated with epigenetic programming events involving
pluripotency [13]. Intriguingly, BORIS protein is seen to
co-localize with self-renewal proteins NANOG and
OCT4 in the nucleus of these cells [13]. However, adap-
tation of hES cells to prolonged growth in culture is
associated with gradual loss of multilineage differentia-
tion capacity along with gradual gain of chromosome 20
(BORIS is mapped at 20q13), increased levels of BORIS
expression and MAGEA4 activation [50]. Consistent
with this is that the levels of BORIS mRNA were
increased more than 10-fold (observed in both passage
132 and 237) upon long term maintenance of H7 hES
cells in culture [50]. Throughout this process of hES
“adaptation to growth in culture” a profound loss of
pluripotency was observed concomitant with loss of the
q arm of chromosome 16 (the locus of CTCF) and gain
of chromosome 20q13 the genetic location BORIS. This
20q13 gain as well as 16q22 loss of heterozygosity
(LOH) with increased BORIS expression parallels a simi-
lar association in cancers [51] that also show CTCF
haplo-insufficiency [52,53]. It is possible that a 16q LOH
may result in a reduction of CTCF which is known to
repress BORIS expression, as does p53 and DNA-
methylation [14]. In this situation these suppressive
effects might also decrease since BORIS expression is
commonly associated with events of global demethyla-
tion [22,54]. Under these circumstances it is possible
that even a slight elevation of BORIS may exert greater
overall epigenetic influence than in a normal situation
where increased competition with CTCF may prevent
DNA binding. Furthermore, this may help explain the
significant fluctuations in the levels of BORIS that coin-
cide with many primary cancers (Table 1). Further ana-
lyses will be required to address this interesting cancer-
associated phenomenon.
BORIS as a vaccine for cancer immunotherapy
Recent studies have provided proof of concept for the
utility of anti-cancer immunotherapy strategies in sev-
eral clinical settings, although with modest efficacy. The
major issues of cancer immunotherapy are the tendency
of tumor cells to escape immune surveillance by indu-
cing tolerance to self-antigens, changing antigenic pro-
files and producing immune suppressing agents.
Therefore, availability of strong and immunogenic
tumor associated antigens and combination of immu-
notherapy with the agents inhibiting immune suppres-
sion could improve the efficacy of immunotherapy
significantly. The ideal characteristics for candidate anti-
gens for cancer immunotherapy are the tissue distribu-
tion that is restricted to tumors, the immunogenicity,
and the essential contribution of the antigen in the
transformation and maintenance of the malignant phe-
notype of tumor cells. Characteristics of BORIS mole-
cule described above and in Figure 3 provide evidence
that BORIS is an attractive target antigen for immu-
notherapeutic strategies to treat different types of can-
cer. Data presented in Table 1 demonstrate that BORIS
expressed in a high percent of primary tumors of differ-
ent origin including breast, melanoma, colon, and pros-
tate. As a cancer testes antigen, it has a strong rational
particularly in tumor types affecting predominantly
females due to the minimal state of intrinsic tolerance.
Anti-BORIS antibodies were detected in the sera of
breast cancer patients (United States Patent 7785814),
confirming its immunogenicity and proving it as a valid
target for anti-tumor immunotherapy.
The characteristics of BORIS molecule described
above along with the preclinical work performed up
today resulted in BORIS being included in the list of
high priority TAAs generated by the NCI Translational
Working Group [55]. However, development of BORIS-
based anti-cancer vaccine requires certain safety con-
cerns to be met. Specifically, because of the DNA bind-
ing and gene activating functions as well as epigenetic
reprogramming function of BORIS, administration of
the functional BORIS protein would pose a hypothetical
risk of BORIS accelerating the progression of cancer. To
alleviate such safety concerns, a target antigen based on
BORIS molecule that lacks the DNA-binding ZF domain
have been generated. To evaluate the potency and mag-
nitude of the immune response, class of immune
response, and to select a particular strategy for eliciting
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anti-tumor immunity we generated and tested DNA
(pmBORIS), protein (mBORIS) and adenoviral
(AdBORIS) vaccines based on truncated mouse BORIS
[56-58]. As was expected, protein-based vaccine induced
high titer of BORIS-specific antibody and Th2 type of
cytokine responses, but not cytolytic activity. In contrast,
DNA and adenovirus based vaccines induced potent
antigen-specific Th1-type response and cytolytic
responses. Molecular adjuvants, plasmids expressing the
cytokines IL-12 and IL-18, augmented the antigen-speci-
fic cellular immune responses in mice immunized with
pmBORIS. Importantly, generated immune responses
mediate cytotoxicity to a wide range of histologically
unrelated tumors (including breast cancer, glioma, plas-
macytoma) in an MHC class I-dependent manner [41].
The protective potency of pmBORIS vaccine was evalu-
ated in a 4T1 stringent mouse model of spontaneous
mammary carcinoma that closely resembles human
breast cancer. Vaccination with pmBORIS along with
pIL12 and pIL18 immunomodulators as well as with
AdBORIS prior to tumor challenge inhibited mouse
mammary tumor growth and prolonged survival of vac-
cinated mice [56][58]. Although prophylactic vaccination
is important for initial proof of concept and efficacy stu-
dies, therapeutic vaccination more accurately reflects the
clinical situation. Our data demonstrate that therapeutic
vaccination of mice with mBORIS-based vaccine after
implantation of poorly immunogenic and very aggressive
4T1 adenocarcinoma significantly inhibits tumor growth
and progression of metastatic disease compared with
control mice [59]. Importantly, infiltrations of both CD4
+ and CD8+ T cells were significantly increased, while
the numbers of myeloid derived suppressor cells
(MDSC) were significantly decreased in tumors, but not
in spleens of vaccinated mice compared to the control
ones. Even in the absence of changes in the splenic
MDSC and TREG populations, vaccination led to the sig-
nificant inhibition of tumor growth and metastatic dis-
ease arguing for strategies that not only elicit strong
anti-cancer immunity, but also robust inhibition of sup-
pressor environment. Taken together these various
observations suggest that BORIS is immunogenic, likely
expressed early in and contributes to the transformation
and in the maintenance of the malignant phenotype, has
a wide expression profile in multiple tumor types
whereas the expression is restricted to testes in normal
tissues. All these features make BORIS very promising
as a target antigen suggesting that BORIS-based thera-
peutic vaccine strategies combined with agents attenuat-
ing tumor associated immune suppression will be very
effective in clinical settings. Another strategy is to use
BORIS based vaccine for prophylactic/preventive vacci-
nation of healthy patients with genetic susceptibility to
cancer. For example using breast cancer diagnostic
Figure 3 BORIS characteristics that make it an attractive target antigen for cancer treatment. Numbers indicate numeric references
associated with each category.
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biomarkers such as BRCA1 [60], BRCA2 [61], and
BORIS-MS2 [45] one could identify the high risk popu-
lation and potentially treat with preventative vaccina-
tion. Ultimately, antigen based immunotherapy
approaches involving ideal target candidates such as
BORIS guided by enhanced genetic analyses may be the
future of cancer medicine and useful for the treatment
of cancer of multiple origins.
Conclusion
In this review we describe a unique molecule, BORIS,
which has a highly conserved 11 zinc finger DNA-bind-
ing domain very similar to its better known paralog,
CTCF. Although thousand papers are published after
the discovery of CTCF very little is known about
BORIS. These two proteins target common DNA bind-
ing sites but BORIS is only expressed in early gameto-
genesis and in multiple cancers, not in differentiated
somatic cells. Evidence indicates that BORIS has an
extensive regulatory role in the cell through complex
epigenetic associations that are influenced by DNA
methylation as well as numerous protein interactions.
The expression profile and regulatory role of BORIS in
cancer makes this an attractive antigen target in cancer
immunotherapy. Several promising approaches toward
the development of a BORIS based cancer vaccines are
being investigated and are likely to be effective in the
treatment of diverse cancers.
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